GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Cyclically Adjusted Revenue per Share

Access Bio (XKRX:950130) Cyclically Adjusted Revenue per Share : ₩7,161.07 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Access Bio Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Access Bio's adjusted revenue per share for the three months ended in Sep. 2024 was ₩617.780. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩7,161.07 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Access Bio's average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-12-14), Access Bio's current stock price is ₩5520.00. Access Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was ₩7,161.07. Access Bio's Cyclically Adjusted PS Ratio of today is 0.77.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Access Bio was 3.65. The lowest was 0.73. And the median was 1.38.


Access Bio Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Access Bio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Cyclically Adjusted Revenue per Share Chart

Access Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 5,941.65 6,867.85

Access Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,850.18 6,867.85 7,043.59 7,102.56 7,161.07

Competitive Comparison of Access Bio's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Access Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Access Bio's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Access Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Access Bio's Cyclically Adjusted PS Ratio falls into.



Access Bio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Access Bio's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=617.78/133.0289*133.0289
=617.780

Current CPI (Sep. 2024) = 133.0289.

Access Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 89.433 99.070 120.089
201503 1,378.742 99.621 1,841.101
201506 423.911 100.684 560.094
201509 282.196 100.392 373.938
201512 262.880 99.792 350.434
201603 311.641 100.470 412.632
201606 328.384 101.688 429.594
201609 865.183 101.861 1,129.916
201612 253.461 101.863 331.011
201703 212.436 102.862 274.738
201706 231.223 103.349 297.626
201709 335.344 104.136 428.388
201712 358.160 104.011 458.082
201803 456.370 105.290 576.604
201806 472.894 106.317 591.709
201809 396.146 106.507 494.794
201812 275.105 105.998 345.261
201903 379.175 107.251 470.312
201906 393.295 108.070 484.129
201909 426.472 108.329 523.709
201912 299.815 108.420 367.866
202003 307.785 108.902 375.976
202006 583.778 108.767 713.995
202009 326.118 109.815 395.057
202012 2,558.261 109.897 3,096.748
202103 6,120.105 111.754 7,285.179
202106 368.742 114.631 427.922
202109 1,157.982 115.734 1,331.023
202112 5,834.839 117.630 6,598.704
202203 21,013.335 121.301 23,044.994
202206 3,259.050 125.017 3,467.917
202209 350.516 125.227 372.355
202212 1,356.218 125.222 1,440.773
202303 6,529.052 127.348 6,820.319
202306 1,917.051 128.729 1,981.090
202309 88.777 129.860 90.944
202312 956.923 129.419 983.612
202403 1,035.095 131.776 1,044.935
202406 657.035 132.554 659.390
202409 617.780 133.029 617.780

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Access Bio  (XKRX:950130) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Access Bio's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5520.00/7161.07
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Access Bio was 3.65. The lowest was 0.73. And the median was 1.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Access Bio Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Access Bio's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Access Bio Business Description

Traded in Other Exchanges
N/A
Address
65 Clyde Road, Suite A, Somerset, NJ, USA, 08873
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio Headlines

No Headlines